Hutchmed Roils Markets With Changing of Its Guard, U.S. Delisting Threat
U.S. securities regulator singles out company for potential delisting, a week after Hutchmed announced its CEO will step down after almost 22 years Key Takeaways U.S. securities regulator says Hutchmed…
RELATED ARTICLES
-
Everest reaches new heights on growing drug sales
1952.HK -
Will Junshi Bio’s loss-making headaches ease with landmark U.S. drug approval?
1877.HK 688180.SHG
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
